Search Results - "Haikala, Heidi M"

Thirty Years of HER3: From Basic Biology to Therapeutic Interventions by Haikala, Heidi M, Jänne, Pasi A

“…HER3 is a pseudokinase member of the EGFR family having a role in both tumor progression and drug resistance. Although HER3 was discovered more than 30 years…”
Get full text

Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis by Nieminen, Anni I, Eskelinen, Vilja M, Haikala, Heidi M, Tervonen, Topi A, Yan, Yan, Partanen, Johanna I, Klefström, Juha

“…Oncogenic transcription factor Myc deregulates the cell cycle and simultaneously reprograms cellular metabolism to meet the biosynthetic and bioenergetic needs…”
Get full text

EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd by Haikala, Heidi M, Lopez, Timothy, Köhler, Jens, Eser, Pinar O, Xu, Man, Zeng, Qing, Teceno, Tyler J, Ngo, Kenneth, Zhao, Yutong, Ivanova, Elena V, Bertram, Arrien A, Leeper, Brittaney A, Chambers, Emily S, Adeni, Anika E, Taus, Luke J, Kuraguchi, Mari, Kirschmeier, Paul T, Yu, Channing, Shiose, Yoshinobu, Kamai, Yasuki, Qiu, Yang, Paweletz, Cloud P, Gokhale, Prafulla C, Jänne, Pasi A

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are the standard-of-care treatment for -mutant non-small cell lung cancers (NSCLC)…”
Get full text

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer by To, Ciric, Beyett, Tyler S, Jang, Jaebong, Feng, William W, Bahcall, Magda, Haikala, Heidi M, Shin, Bo H, Heppner, David E, Rana, Jaimin K, Leeper, Brittaney A, Soroko, Kara M, Poitras, Michael J, Gokhale, Prafulla C, Kobayashi, Yoshihisa, Wahid, Kamal, Kurppa, Kari J, Gero, Thomas W, Cameron, Michael D, Ogino, Atsuko, Mushajiang, Mierzhati, Xu, Chunxiao, Zhang, Yanxi, Scott, David A, Eck, Michael J, Gray, Nathanael S, Jänne, Pasi A

“…Epidermal growth factor receptor (EGFR) therapy using small-molecule tyrosine kinase inhibitors (TKIs) is initially efficacious in patients with EGFR-mutant…”
Get full text

Sortilin‐related receptor is a druggable therapeutic target in breast cancer by Al‐Akhrass, Hussein, Pietilä, Mika, Lilja, Johanna, Vesilahti, Ella‐Maria, Anttila, Johanna M., Haikala, Heidi M., Munne, Pauliina M., Klefström, Juha, Peuhu, Emilia, Ivaska, Johanna

“…In breast cancer, the currently approved anti‐receptor tyrosine‐protein kinase erbB‐2 (HER2) therapies do not fully meet the expected clinical goals due to…”
Get full text

Inhibition of CDK12 elevates cancer cell dependence on P-TEFb by stimulation of RNA polymerase II pause release by Wang, Zhijia, Himanen, Samu V, Haikala, Heidi M, Friedel, Caroline C, Vihervaara, Anniina, Barborič, Matjaž

“…Abstract P-TEFb and CDK12 facilitate transcriptional elongation by RNA polymerase II. Given the prominence of both kinases in cancer, gaining a better…”
Get full text

UBR5 Is Coamplified with MYC in Breast Tumors and Encodes an Ubiquitin Ligase That Limits MYC-Dependent Apoptosis by Qiao, Xi, Liu, Ying, Prada, Maria Llamazares, Mohan, Aravind K, Gupta, Abhishekh, Jaiswal, Alok, Sharma, Mukund, Merisaari, Joni, Haikala, Heidi M, Talvinen, Kati, Yetukuri, Laxman, Pylvänäinen, Joanna W, Klefström, Juha, Kronqvist, Pauliina, Meinander, Annika, Aittokallio, Tero, Hietakangas, Ville, Eilers, Martin, Westermarck, Jukka

“…For maximal oncogenic activity, cellular MYC protein levels need to be tightly controlled so that they do not induce apoptosis. Here, we show how ubiquitin…”
Get full text

Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer by Ricciuti, Biagio, Son, Jieun, Okoro, Jeffrey J, Mira, Alessia, Patrucco, Enrico, Eum, Yoonji, Wang, Xinan, Paranal, Raymond, Wang, Haiyun, Lin, Mika, Haikala, Heidi M, Li, Jiaqi, Xu, Yue, Alessi, Joao Victor, Chhoeu, Chhayheng, Redig, Amanda J, Köhler, Jens, Dholakia, Kshiti H, Chen, Yunhan, Richard, Elodie, Nokin, Marie-Julie, Santamaria, David, Gokhale, Prafulla C, Awad, Mark M, Jänne, Pasi A, Ambrogio, Chiara

“…Activating missense mutations of KRAS are the most frequent oncogenic driver events in lung adenocarcinoma (LUAD). However, KRAS isoforms are highly…”
Get full text

A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non-Small Cell Lung Cancer by Son, Jieun, Jang, Jaebong, Beyett, Tyler S, Eum, Yoonji, Haikala, Heidi M, Verano, Alyssa, Lin, Mika, Hatcher, John M, Kwiatkowski, Nicholas P, Eser, Pinar Ö, Poitras, Michael J, Wang, Stephen, Xu, Man, Gokhale, Prafulla C, Cameron, Michael D, Eck, Michael J, Gray, Nathanael S, Jänne, Pasi A

“…In-frame insertions in exon 20 of HER2 are the most common HER2 mutations in patients with non-small cell lung cancer (NSCLC), a disease in which approved…”
Get full text

Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy by Haikala, Heidi M., Anttila, Johanna M., Marques, Elsa, Raatikainen, Tiina, Ilander, Mette, Hakanen, Henna, Ala-Hongisto, Hanna, Savelius, Mariel, Balboa, Diego, Von Eyss, Bjoern, Eskelinen, Vilja, Munne, Pauliina, Nieminen, Anni I., Otonkoski, Timo, Schüler, Julia, Laajala, Teemu D., Aittokallio, Tero, Sihto, Harri, Mattson, Johanna, Heikkilä, Päivi, Leidenius, Marjut, Joensuu, Heikki, Mustjoki, Satu, Kovanen, Panu, Eilers, Martin, Leverson, Joel D., Klefström, Juha

“…Elevated MYC expression sensitizes tumor cells to apoptosis but the therapeutic potential of this mechanism remains unclear. We find, in a model of MYC-driven…”
Get full text

Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing by Ollila-Raj, Hely, Murumägi, Astrid, Pellinen, Teijo, Arjama, Mariliina, Sutinen, Eva, Volmonen, Kirsi, Haikala, Heidi M., Kallioniemi, Olli, Mäyränpää, Mikko I., Ilonen, Ilkka

“…•Standard of care for pleural mesothelioma has not changed for 20 years.•Repurposing of already approved drugs may result in more effective…”
Get full text

Repression of SRF target genes is critical for Myc-dependent apoptosis of epithelial cells by Wiese, Katrin E, Haikala, Heidi M, von Eyss, Björn, Wolf, Elmar, Esnault, Cyril, Rosenwald, Andreas, Treisman, Richard, Klefström, Juha, Eilers, Martin

“…Oncogenic levels of Myc expression sensitize cells to multiple apoptotic stimuli, and this protects long‐lived organisms from cancer development. How cells…”
Get full text

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR -mutant lung cancer by Eser, Pınar Özden, Paranal, Raymond M, Son, Jieun, Ivanova, Elena, Kuang, Yanan, Haikala, Heidi M, To, Ciric, Okoro, Jeffrey J, Dholakia, Kshiti H, Choi, Jihyun, Eum, Yoonji, Ogino, Atsuko, Missios, Pavlos, Ercan, Dalia, Xu, Man, Poitras, Michael J, Wang, Stephen, Ngo, Kenneth, Dills, Michael, Yanagita, Masahiko, Lopez, Timothy, Lin, Mika, Tsai, Jeanelle, Floch, Nicolas, Chambers, Emily S, Heng, Jennifer, Anjum, Rana, Santucci, Alison D, Michael, Kesi, Schuller, Alwin G, Cross, Darren, Smith, Paul D, Oxnard, Geoffrey R, Barbie, David A, Sholl, Lynette M, Bahcall, Magda, Palakurthi, Sangeetha, Gokhale, Prafulla C, Paweletz, Cloud P, Daley, George Q, Jänne, Pasi A

“…The clinical efficacy of epidermal growth factor receptor (EGFR)–targeted therapy in -mutant non–small cell lung cancer is limited by the development of drug…”
Get more information

Myc requires RhoA/SRF to reprogram glutamine metabolism by Haikala, Heidi M, Marques, Elsa, Turunen, Mikko, Klefström, Juha

“…RhoA regulates actin cytoskeleton but recent evidence suggest a role for this conserved Rho GTPase also in other cellular processes, including transcriptional…”
Get full text

MYC-induced apoptosis in mammary epithelial cells is associated with repression of lineage-specific gene signatures by Haikala, Heidi M., Klefström, Juha, Eilers, Martin, Wiese, Katrin E.

“…Apoptosis caused by deregulated MYC expression is a prototype example of intrinsic tumor suppression. However, it is still unclear how supraphysiological MYC…”
Get full text

MYC and AMPK-Save Energy or Die by Haikala, Heidi M, Anttila, Johanna M, Klefström, Juha

“…MYC sustains non-stop proliferation by altering metabolic machinery to support growth of cell mass. As part of the metabolic transformation MYC promotes lipid,…”
Get full text

Ex vivo modeling of precision immuno-oncology responses in lung cancer by Alsaed, Bassel, Smolander, Johannes, Laitinen, Hanna, Lin, Linh, Bobik, Nina, Lahtinen, Lilja, Räsänen, Mikko, Jansouz, Shadi, Peltonen, Karita, Jokinen, Emmi, Klievink, Jay, Ganesh, Keerthana, Ainola, Mari, Sutinen, Eva, Rönty, Mikko, Narvi, Elli, Thotakura, Anil, Saharinen, Pipsa, Mustjoki, Satu, Ilonen, Ilkka, Haikala, Heidi M

“…Despite immunotherapy's promise in cancer treatment, patient responses vary substantially because of the individual nature of the immune system and the lack of…”
Get full text

Publisher Correction: Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy by Haikala, Heidi M., Anttila, Johanna M., Marques, Elsa, Raatikainen, Tiina, Ilander, Mette, Hakanen, Henna, Ala-Hongisto, Hanna, Savelius, Mariel, Balboa, Diego, Von Eyss, Bjoern, Eskelinen, Vilja, Munne, Pauliina, Nieminen, Anni I., Otonkoski, Timo, Schüler, Julia, Laajala, Teemu D., Aittokallio, Tero, Sihto, Harri, Mattson, Johanna, Heikkilä, Päivi, Leidenius, Marjut, Joensuu, Heikki, Mustjoki, Satu, Kovanen, Panu, Eilers, Martin, Leverson, Joel D., Klefström, Juha

“…The original version of this Article contained an error in Fig. 7. In panel b, the survival curves were shifted relative to the y axis. This error has been…”
Get full text

30 years of HER3: From basic biology to therapeutic interventions by Haikala, Heidi M., Jänne, Pasi A.

“…HER3 is a pseudo-kinase member of the EGFR family having a role in both tumor progression and drug resistance. Although HER3 was discovered more than 30 years…”
Get full text

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway by Kurppa, Kari J., Liu, Yao, To, Ciric, Zhang, Tinghu, Fan, Mengyang, Vajdi, Amir, Knelson, Erik H., Xie, Yingtian, Lim, Klothilda, Cejas, Paloma, Portell, Andrew, Lizotte, Patrick H., Ficarro, Scott B., Li, Shuai, Chen, Ting, Haikala, Heidi M., Wang, Haiyun, Bahcall, Magda, Gao, Yang, Shalhout, Sophia, Boettcher, Steffen, Shin, Bo Hee, Thai, Tran, Wilkens, Margaret K., Tillgren, Michelle L., Mushajiang, Mierzhati, Xu, Man, Choi, Jihyun, Bertram, Arrien A., Ebert, Benjamin L., Beroukhim, Rameen, Bandopadhayay, Pratiti, Awad, Mark M., Gokhale, Prafulla C., Kirschmeier, Paul T., Marto, Jarrod A., Camargo, Fernando D., Haq, Rizwan, Paweletz, Cloud P., Wong, Kwok-Kin, Barbie, David A., Long, Henry W., Gray, Nathanael S., Jänne, Pasi A.

“…Eradicating tumor dormancy that develops following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small…”
Get full text